首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and biological effects of novel 2-amino-3-(4-chlorobenzoyl)-4- substituted thiophenes as allosteric enhancers of the A1 adenosine receptor
【24h】

Synthesis and biological effects of novel 2-amino-3-(4-chlorobenzoyl)-4- substituted thiophenes as allosteric enhancers of the A1 adenosine receptor

机译:新型2-氨基-3-(4-氯苯甲酰基)-4-取代的噻吩作为A1腺苷受体变构增强剂的合成及生物学效应

获取原文
获取原文并翻译 | 示例
       

摘要

Allosteric enhancers for the A1 adenosine receptor represent a novel and unique drug design strategy to augment the response to endogenous adenosine in a site- and event-specific manner.We have previously investigated a detailed structure-activity relationship study around a wide series of 2-amino-3-aroyl-4-[(4-arylpiperazin-1-yl)methyl]thiophene derivatives as potent allosteric enhancers of the A1 adenosine receptor. In this manuscript we report our investigation on the influence on allosteric enhancer activity of further substitution at the 4-position of the 2-amino-3-(4-chlorobenzoyl)- thiophene system to explore bulk tolerance by replacement of the arylpiperazine moiety with a series of fused indole nuclei corresponding to 1,2,3,4-tetrahydropyrazino[1,2-a ]indole, 1,2,3,4,10,10a-hexahydropyrazino[1,2- a]indole, tet-rahydro- γ-carboline, tetrahydroisoquinoline, spiro-1,3-benzodioxolepiperidine, aliphatic tertiary amine, N-alkylaniline, aryl ether and aryl thioether templates. The 1,2,3,4-tetrahydropyrazino[1,2- a]indole derivatives 3-ec and 3- were the most active compounds in binding (saturation and competition) and functional cAMP studies, being able to potentiate agonist [3H]CCPA binding to the A1 receptor. This study also shows that it is possible to obtain a good separation between allosteric enhancement and antagonistic activity at the A1 adenosine receptor.
机译:A1腺苷受体的变构增强剂代表了一种新颖且独特的药物设计策略,可以以位点和事件特定的方式增强对内源性腺苷的反应。我们之前围绕2个广泛的2系列研究了详细的结构-活性关系研究氨基-3-芳酰基-4-[(4-芳基哌嗪-1-基)甲基]噻吩衍生物作为A1腺苷受体的有效变构增强剂。在本手稿中,我们报告了我们对2-氨基-3-(4-氯苯甲酰基)-噻吩系统的4-位进一步取代对变构增强剂活性的影响的研究,以探索通过用芳基哌嗪部分取代芳基哌嗪部分来测定体积耐受性1,2,3,4-四氢吡嗪并[1,2-a]吲哚,1,2,3,4,10,10a-六氢吡嗪并[1,2-a]吲哚和四氢萘的稠合吲哚核的系列-γ-咔啉,四氢异喹啉,螺-1,3-苯并二氧戊哌啶,脂族叔胺,N-烷基苯胺,芳基醚和芳基硫醚模板。 1,2,3,4-四氢吡嗪并[1,2-a]吲哚衍生物3-ec和3-是结合(饱和和竞争)和功能性cAMP研究中活性最高的化合物,能够增强激动剂[3H] CCPA与A1受体结合。这项研究还表明,有可能在变构增强和对A1腺苷受体的拮抗活性之间获得良好的分离。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号